How CROs can bridge the gap between pharma expectations and patient reality
Pharmaceutical companies design clinical trials with defined endpoints, strict deadlines, and budget targets. Patients live in a very different world — one of fear, fatigue, complicated schedules, and financial stress. This gap is one of the biggest reasons clinical trials struggle.
Why CROs are uniquely positioned to fix this
CROs interact with both sides of the equation every day. They work directly with pharmaceutical sponsors on strategy and design, while also managing sites, coordinators, and patients on the ground. This dual visibility gives CROs something that neither sponsors nor sites have: a complete picture of where expectations are being met and why. But capturing this opportunity requires moving beyond reactive execution.
1. Protocol design that real patients can follow
Most protocol problems are apparent long before the first patient is enrolled — if anyone is willing to study them. Overly restrictive inclusion criteria, excessive on-site visits, and rigid scheduling that ignores the lifestyles of real patients all undermine enrolment. Patient-centred CROs intervene early by conducting patient feasibility reviews during protocol development, using historical data to identify workload elements that have led to exclusions in similar studies, and advocating for remote visits and flexible windows where evidence supports them.
2. Rethinking recruitment — from numbers to relationships
By reframing enrolment as a matter of trust, CROs can reach diverse populations missed by traditional site databases. This means partnering with patient advocacy organisations who already hold community trust, using digital and social platforms to reach patients where they already spend time, and training site staff to communicate with empathy — not just efficiency.
3. Decentralised clinical trial models
Nothing bridges the pharmaceutical-patient gap more effectively than bringing clinical trials closer to patients. DCTs are no longer experimental — they are a proven model for increasing access, reducing dropouts, and generating real-world data. Telemedicine visits, home care for specimen collection, wearable devices for continuous data collection, and direct drug delivery all reduce the burden on participants.
4. Communicate as people, not contracts
One of the most preventable reasons a patient drops out is feeling uninformed or unappreciated. CROs can change this by rewriting informed consent in simple, accessible language, appointing dedicated patient contacts at all sites, using digital platforms for regular personalised updates, and sharing summary results after the study is complete.
The business case
A single day of enrolment delay can cost up to $8 million in lost revenue. CROs willing to challenge unrealistic protocol assumptions with evidence — and measure success by patient retention scores, not just time to resolution — provide substantially higher value to sponsors. CROs that invest in patient-centric capabilities do not just conduct better studies. They win more business.
Prepared by Paspigioni team: Marika Gergedava, MD and Nina Biblaia